Simone Bertini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1836498/publications.pdf

Version: 2024-02-01

304602 330025 1,574 69 22 37 h-index citations g-index papers 69 69 69 2496 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials. Current Medicinal Chemistry, 2010, 17, 672-697.	1.2	169
2	Synthesis, Antifungal Activity, and Molecular Modeling Studies of New Inverted Oxime Ethers of Oxiconazole. Journal of Medicinal Chemistry, 2002, 45, 4903-4912.	2.9	111
3	Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells. Journal of Medicinal Chemistry, 2005, 48, 6783-6786.	2.9	69
4	Cytotoxic Activity of Oleocanthal Isolated from Virgin Olive Oil on Human Melanoma Cells. Nutrition and Cancer, 2016, 68, 873-877.	0.9	65
5	Oleocanthal and oleacein contribute to the in vitro therapeutic potential of extra virgin oil-derived extracts in non-melanoma skin cancer. Toxicology in Vitro, 2018, 52, 243-250.	1.1	57
6	Purification, Enzymatic Characterization, and Inhibition of the Z-Farnesyl Diphosphate Synthase from Mycobacterium tuberculosis. Journal of Biological Chemistry, 2001, 276, 11624-11630.	1.6	55
7	N6â€isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB Journal, 2006, 20, 412-418.	0.2	52
8	Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold. European Journal of Medicinal Chemistry, 2012, 52, 284-294.	2.6	50
9	Design, Synthesis, and Characterization of the Antitumor Activity of Novel Ceramide Analoguesâ€. Journal of Medicinal Chemistry, 2001, 44, 3994-4000.	2.9	49
10	Identification of the First Synthetic Allosteric Modulator of the CB ₂ Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief. Journal of Medicinal Chemistry, 2019, 62, 276-287.	2.9	47
11	CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin- $2(1 < i > H < /i >)$ -one-3-carboxamides. Journal of Medicinal Chemistry, 2014, 57, 8777-8791.	2.9	46
12	Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6923-6927.	1.0	42
13	New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno–modulatory activity. European Journal of Medicinal Chemistry, 2015, 97, 10-18.	2.6	40
14	Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor \hat{l}^2 . Journal of Medicinal Chemistry, 2009, 52, 858-867.	2.9	38
15	Salicylaldoxime Moiety as a Phenolic "A-Ring―Substitute in Estrogen Receptor Ligands. Journal of Medicinal Chemistry, 2001, 44, 4288-4291.	2.9	34
16	Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties. Bioorganic and Medicinal Chemistry, 2010, 18, 6715-6724.	1.4	30
17	Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-Substituted 3,4-Diarylsalicylaldoximes on estrogen receptors \hat{l}_{\pm} and \hat{l}_{\pm}^2 . Bioorganic and Medicinal Chemistry, 2003, 11, 1247-1257.	1.4	29
18	Estrogen receptor ligands: a patent review update. Expert Opinion on Therapeutic Patents, 2013, 23, 1247-1271.	2.4	29

#	Article	lF	Citations
19	Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes. Journal of Medicinal Chemistry, 2006, 49, 5001-5012.	2.9	27
20	αâ€Naphthylaminopropanâ€2â€ol Derivatives as BACE1 Inhibitors. ChemMedChem, 2008, 3, 1530-1534.	1.6	26
21	Monoaryl-Substituted Salicylaldoximes as Ligands for Estrogen Receptor \hat{l}^2 . Journal of Medicinal Chemistry, 2008, 51, 1344-1351.	2.9	26
22	Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes. European Journal of Medicinal Chemistry, 2011, 46, 2453-2462.	2.6	25
23	Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery. Future Medicinal Chemistry, 2019, 11, 2019-2037.	1.1	23
24	Carbazole-containing arylcarboxamides as BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6657-6661.	1.0	22
25	Highly Selective Salicylketoxime-Based Estrogen Receptor \hat{I}^2 Agonists Display Antiproliferative Activities in a Glioma Model. Journal of Medicinal Chemistry, 2015, 58, 1184-1194.	2.9	22
26	Novel Estrogen Receptor Ligands Based on an Anthranylaldoxime Structure:Â Role of the Phenol-Type Pseudocycle in the Binding Process. Journal of Medicinal Chemistry, 2003, 46, 4032-4042.	2.9	20
27	Design, synthesis and preliminary evaluation of 18F-labelled 1,8-naphthyridin- and quinolin-2-one-3-carboxamide derivatives for PET imaging of CB2 cannabinoid receptor. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2532-2535.	1.0	19
28	7-Nitrobenzofurazan (NBD) derivatives of 5′-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A3 adenosine receptors. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3023-3026.	1.0	18
29	A Theoretical Study To Investigate D2DAR/D4DAR Selectivity:  Receptor Modeling and Molecular Docking of Dopaminergic Ligands. Journal of Medicinal Chemistry, 2006, 49, 1397-1407.	2.9	18
30	Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands. European Journal of Medicinal Chemistry, 2015, 90, 526-536.	2.6	18
31	Multi-targeted ChEI-copper chelating molecules as neuroprotective agents. European Journal of Medicinal Chemistry, 2019, 174, 216-225.	2.6	18
32	Composition of health-promoting phenolic compounds in two extra virgin olive oils and diversity of associated yeasts. Journal of Food Composition and Analysis, 2018, 74, 27-33.	1.9	17
33	Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system. European Journal of Medicinal Chemistry, 2018, 154, 155-171.	2.6	17
34	1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor. European Journal of Medicinal Chemistry, 2014, 74, 524-532.	2.6	16
35	Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. Medicines (Basel, Switzerland), 2018, 5, 91.	0.7	16
36	Ceramide analogues in apoptosis: a new strategy for anticancer drug development. Il Farmaco, 2003, 58, 205-211.	0.9	14

3

#	Article	IF	CITATIONS
37	Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor. Bioorganic and Medicinal Chemistry, 2017, 25, 6427-6434.	1.4	14
38	Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist. Life, 2020, 10, 333.	1.1	14
39	Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 419-426.	0.4	13
40	Synthesis and pharmacological evaluation of new biphenylic derivatives as CB 2 receptor ligands. European Journal of Medicinal Chemistry, 2016, 116, 252-266.	2.6	13
41	Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 1511-1515.	1.4	12
42	The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis. European Journal of Medicinal Chemistry, 2020, 208, 112858.	2.6	12
43	Metabolically labile cannabinoid esters: A â€~soft drug' approach for the development of cannabinoid-based therapeutic drugs. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4878-4881.	1.0	10
44	Modification on the 1,2-dihydro-2-oxo-pyridine-3-carboxamide core to obtain multi-target modulators of endocannabinoid system. Bioorganic Chemistry, 2020, 94, 103353.	2.0	10
45	Cannabinoid-Based Medicines and Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2021, 1264, 111-129.	0.8	10
46	Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4812-4816.	1.0	9
47	Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB2R modulators in neurodegenerative diseases. Pharmacological Research, 2021, 170, 105607.	3.1	9
48	Content Variations in Oleocanthalic Acid and Other Phenolic Compounds in Extra-Virgin Olive Oil during Storage. Foods, 2022, 11, 1354.	1.9	8
49	BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides. Bioorganic and Medicinal Chemistry, 2010, 18, 7991-7996.	1.4	7
50	4-[6-(Dansylamino)hexylamino]-7-methyl-2-phenyl-1,8-naphthyridine as a new potential fluorescent probe for studying A1-adenosine receptor. Il Farmaco, 2002, 57, 783-786.	0.9	6
51	Efficient application of monolithic silica column to determination of illicit heroin street sample by HPLC. Il Farmaco, 2004, 59, 237-239.	0.9	6
52	Development of an HPLC/UV assay for the evaluation of inhibitors of human recombinant monoacylglycerol lipase. Journal of Pharmaceutical and Biomedical Analysis, 2015, 108, 113-121.	1.4	6
53	Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4405-4408.	1.0	5
54	Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)-Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition. ChemMedChem, 2006, 1, 218-224.	1.6	5

#	Article	IF	CITATIONS
55	Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor. European Journal of Medicinal Chemistry, 2021, 211, 113116.	2.6	5
56	Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors. Il Farmaco, 2004, 59, 887-892.	0.9	4
57	Antiproliferative Activity and Cell Cycle Analysis of 2-(3,5-Dihydroxyphenyl)-6-Hydroxybenzothiazole on MCF-7 Breast and HCT-15 Colon Cancer Cell Lines. DNA and Cell Biology, 2011, 30, 617-621.	0.9	4
58	Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. Il Farmaco, 2003, 58, 85-89.	0.9	3
59	Synthesis and antiviral properties of novel analogues of monophosphate and diphosphate bioactive forms of acyclovir. Il Farmaco, 2000, 55, 322-327.	0.9	2
60	Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands. Il Farmaco, 2004, 59, 601-607.	0.9	2
61	Application of An Improved HPLC-FL Method to Screen Serine Palmitoyl Transferase Inhibitors. Molecules, 2017, 22, 1198.	1.7	2
62	Novel Dual PDK1/AurK-A Inhibitors for Cancer Therapy: Med Chem Evolution and Crystallographic Investigation. Proceedings (mdpi), 2019, 22, .	0.2	2
63	CB1 receptor binding sites for NAM and PAM: A first approach for studying, new nâ€'butylâ€'diphenylcarboxamides as allosteric modulators. European Journal of Pharmaceutical Sciences, 2022, 169, 106088.	1.9	2
64	Novel Potent and Selective Agonists of the GPR55 Receptor Based on the 3-Benzylquinolin-2(1H)-One Scaffold. Pharmaceuticals, 2022, 15, 768.	1.7	2
65	Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity. Il Farmaco, 2003, 58, 1277-1281.	0.9	1
66	Stable propylphosphonic acid analogues of geranylgeranyl diphosphate possessing inhibitory activity on geranylgeranyl protein transferase. Il Farmaco, 2004, 59, 857-861.	0.9	1
67	PSNCBAM-1 analogs: Structural evolutions and allosteric properties at cannabinoid CB1 receptor. European Journal of Medicinal Chemistry, 2020, 203, 112606.	2.6	1
68	Biphenyl-Derivatives Possessing Tertiary Amino Groups as & Samp;#946;-Secretase (BACE1) Inhibitors. Letters in Drug Design and Discovery, 2010, 7, 507-515.	0.4	0
69	Development of Methods for Recovering Endotoxins from Surfaces and from Air in Production Environment of Injectable Drugs. PDA Journal of Pharmaceutical Science and Technology, 2017, 71, 502-510.	0.3	0